MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway
- 73 Downloads
MicroRNAs are involved in each stage of tumor development. Activation of the hepatocyte growth factor (HGF)/c-Met axis facilitates the proliferation and migration of cancer cells, and the HGF/c-MET pathway provides potential targets for anticancer treatment. However, the interaction between HGF and miRNAs in hepatocellular carcinoma (HCC) remains unknown. Previous studies have shown that miR-101 is downregulated in various types of cancer and acts as a tumor suppressor, but the role of miR-101 in HCC has not yet been well defined. Here, we show that HGF is upregulated while microRNA-101-3p is significantly downregulated in the tumor tissues of HCC. By combining bioinformatics analysis and luciferase reporter assays, we demonstrated that HGF is a direct target of miR-101. In vitro experiments indicated that miR-101 inhibits the migration and proliferation of HCC cells by targeting the HGF/c-MET axis, and in vivo studies showed that overexpressed miR-101 dramatically suppresses tumor growth. Therefore, the present study identifies miR-101 as a negative regulator of HGF/c-MET and suggests that miRNAs can be used as targeted drugs for the clinical treatment of HCC.
KeywordsHepatocellular carcinoma miR-101 HGF c-MET
This study was supporting by Hunan Natural Science Youth Fund Project (Project number:2018JJ3784. Project name:Molecular mechanism of miR-1181 involvement in promoting proliferation and survival of hepatocellular). The funder had no role in study design; collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit this article for publication.
Compliance with ethical standards
Conflict of interests
Yang Liu declares that she has no conflict of interest. Juan Tan declares that she has no conflict of interest. Shuangyan Ou declares that she has no conflict of interest. Jun Chen declares that he has no conflict of interest. Limin Chen declares that she has no conflict of interest.
All applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 6.Mi J, Hooker E, Balog S, Zeng H, Johnson DT, He Y, Yu EJ, Wu H, Le V, Lee DH, Aldahl J, Gonzalgo ML, Sun Z (2018) Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumoraggressiveness in the murine prostate. J Biol Chem 293:20123–20136. https://doi.org/10.1074/jbc.RA118.005395 CrossRefGoogle Scholar
- 9.Garajova I, Giovannetti E, Biasco G, Peters GJ (2015) c-Met as a Target for Personalized Therapy. Transl Oncogenomics 7:13–31Google Scholar
- 10.Hu CT, Wu JR, Cheng CC, Wu WS (2017) The therapeutic targeting of HGF/c-met signaling in hepatocellular carcinoma: alternative approaches. Cancers (Basel) 9Google Scholar
- 21.Gong BD, Xie Q, Wang L, Xiang XG, Lin LY, Zhao GD, Wang H, Yu H (2009) Real-time quantification of microRNAs in Huh7 cells by stem-loop reverse transcriptase polymerase chain reaction. Zhonghua Gan Zang Bing Za Zhi 17:603–606Google Scholar
- 28.Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R (2015) Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 33:1008–1014CrossRefGoogle Scholar
- 33.Zhang JJ, Wang CY, Hua L, Yao KH, Chen JT, Hu JH (2015) miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2. Int J Clin Exp Pathol 8:5168–5174Google Scholar
- 34.Kabir TD, Ganda C, Brown RM, Beveridge DJ, Richardson KL, Chaturvedi V, Candy P, Epis M, Wintle L, Kalinowski F, Kopp C, Stuart LM, Yeoh GC, George J, Leedman PJ (2018) A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology 67:216–231CrossRefGoogle Scholar
- 35.He R, Yang L, Lin X, Chen X, Lin X, Wei F, Liang X, Luo Y, Wu Y, Gan T, Dang Y, Chen G (2015) MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. Int J Clin Exp Pathol 8:15632–15641Google Scholar